热门资讯> 正文
Clearmind签署迷幻化合物用于精神障碍治疗的协议
2024-04-17 20:59
- Clearmind Medicine (NASDAQ:CMND) announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
- Under the terms of the agreement, Clearmind receives exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s portfolio in addiction and mental health treatments.
- Source: Press Release
More on Clearmind Medicine Inc.
- Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation
- SciSparc gains as Clearmind partnership yields 3 new international patent applications
- Financial information for Clearmind Medicine Inc.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
